Skip to content
Editorial illustration for Can PARP inhibitors treat blood cancers beyond BRCA mutations?

Can PARP inhibitors treat blood cancers beyond BRCA mutations?

CancerSnoop Research Explained
At a glance

PARP inhibitors blood cancer: Some blood cancers have mutations that reactivate parts of DNA called transposable elements (TEs). These TEs cause DNA damage and trigger immune responses. Scientists are investigating if blocking a DNA repair protein called PARP can kill cancer cells dependent on TE activity. Reference 1

Evidence Coverage

This CancerSnoop article is based on published abstracts. The full methods and analyses were not independently reviewed.

What Did the Researchers Study?

A recent review explains that blood cancers with certain epigenetic mutations lead to TE reactivation. This causes DNA damage and makes the cancer cells rely on PARP for repair. Blocking PARP in these cancers causes synthetic lethality, meaning the cancer cells die because they cannot fix the damage. This TE-PARP connection is a new way to target blood cancers. Reference 1

What Did the Study Find?

The review highlights that mutations in genes like ASXL1 and EZH2 allow TEs to become active, causing DNA damage. These cancers respond to PARP inhibitors because blocking PARP overwhelms their DNA repair ability. This effect does not depend on defects in the usual homologous recombination (HR) DNA repair pathway targeted by PARP inhibitors in other cancers. This suggests PARP inhibitors might help treat more blood cancer patients than previously thought. Reference 1

What the study means in plain English
What improved Blood cancers with ASXL1/EZH2 mutations show sensitivity to PARP inhibitors due to TE-driven DNA damage. Reference 1
What remains unclear It is unclear how well preclinical findings on the TE-PARP axis will translate to effective patient treatments. Reference 1

How Does the Supporting Research Fit?

A study using mouse models and patient samples found that ASXL1/EZH2-mutated blood cancers are sensitive to PARP inhibitors. They also showed that reverse transcriptase inhibitors, which block the TE life cycle, can stop this PARP inhibitor sensitivity. This supports that TE activity underlies the sensitivity to PARP inhibition. However, these findings come from preclinical work and early patient data, needing further trials to confirm clinical benefit. Reference 2

What Does the Guidance Say?

PARP inhibitors are approved for breast and ovarian cancers with BRCA gene mutations that impair HR DNA repair. These cancers depend on PARP for survival, so blocking PARP kills them. The current research suggests blood cancers with epigenetic mutations may also be vulnerable, even without HR defects. This could expand PARP inhibitor use beyond current cases, possibly with immunotherapy. Reference 3

What Remains Uncertain?

The main source is a review article summarizing existing research rather than a new clinical trial. Much evidence comes from lab and animal studies, with limited human clinical data. The exact patient groups who would benefit remain undefined. It is uncertain how well these findings will translate to everyday clinical practice. More clinical trials are necessary to establish safety and effectiveness. Reference 1

CancerSnoop Bottom Line

CancerSnoop Bottom Line

Blood cancers with some epigenetic mutations show promise for treatment with PARP inhibitors due to TE-driven DNA damage. Most evidence is preclinical, so clinical trials are needed before changing treatment guidelines.

Sources and References

CancerSnoop Note: This article provides educational information. Discuss decisions about cancer care with your care team.

SHARE THIS EVIDENCE
WhatsApp ↗
Back To Top